Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Krsnaa Diagnostics

    Jump to

    • Krsnaa Diagnost Consolidated December 2025 Net Sales at Rs 181.20 crore, up 3.83% Y-o-Y

    • Krsnaa Diagnost Standalone December 2025 Net Sales at Rs 159.43 crore, down 3.47% Y-o-Y

    • Stocks to Watch Today: Federal Bank, Nykaa, Bharti Airtel, Tata Motors PV, Hero MotoCorp, Bharti Hexacom, Kaynes Tech, VA Tech Wabag in focus on 06 February

      Stocks to Watch, 06 Feb: Stocks like Bharti Airtel, Tata Motors Passenger Vehicles, Berger Paints India, Hero MotoCorp, FSN E-Commerce Ventures Nykaa, Physicswallah, Bharti Hexacom, KNR Constructions, Rail Vikas Nigam, and Astral will be in focus on February 6.

    • Krsnaa Diagnostics: Steering towards new growth horizons

      The company is targeting 40-50% of revenue mix from its retail business

    • Krsnaa Diagnost Standalone September 2025 Net Sales at Rs 182.88 crore, up 2.33% Y-o-Y

    • Krsnaa Diagnost Consolidated September 2025 Net Sales at Rs 205.99 crore, up 10.55% Y-o-Y

    • Krsnaa Diagnost Consolidated September 2025 Net Sales at Rs 205.99 crore, up 10.55% Y-o-Y

    • Krsnaa Diagnost Consolidated September 2025 Net Sales at Rs 205.99 crore, up 10.55% Y-o-Y

    • Krsnaa Diagnostics: Chasing new avenues for growth

      Optimistic guidance for FY26; the B2C segment should act as a key growth lever

    • Krsnaa Diagnost Consolidated June 2025 Net Sales at Rs 192.98 crore, up 13.36% Y-o-Y

    • Krsnaa Diagnostics receives fresh Letter of Award from Rajasthan, ending two-year long wait after litigation delayed expansion

      Krsnaa Diagnostics and TCIL initiated legal proceedings to challenge the cancellation and in August 2023, the Rajasthan High Court reinstated the contract, thus reviving the agreement with the Krsnaa–TCIL consortium.

    • Krsnaa Diagnost Standalone March 2025 Net Sales at Rs 174.65 crore, up 9.62% Y-o-Y

    • Krsnaa Diagnost Consolidated March 2025 Net Sales at Rs 186.08 crore, up 11.9% Y-o-Y

    • Krsnaa Diagnost Consolidated December 2024 Net Sales at Rs 174.51 crore, up 10.23% Y-o-Y

    • Krsnaa Diagnost Standalone December 2024 Net Sales at Rs 165.16 crore, up 8.98% Y-o-Y

    • Trade Spotlight: How should you trade Ashok Leyland, Mastek, Krsnaa Diagnostics, Federal Bank, Trent, Coromandel International, and others on Monday?

      The positive momentum in the market is likely to continue in the upcoming session, but bulls need to be cautious given the higher volatility. Below are some trading ideas for the near term.

    • Krsnaa Diagnost Consolidated September 2024 Net Sales at Rs 186.34 crore, up 19.87% Y-o-Y

    • Krsnaa Diagnost Standalone September 2024 Net Sales at Rs 178.72 crore, up 21.7% Y-o-Y

    • Krsnaa Diagnostics shares hit 52-week high on winning two projects

      Krsnaa Diagnostics Share Price |

    • Stock Radar: TCS, IREDA, Krsnaa Diagnostics, Oberoi Realty, Bandhan Bank, Mazagon Dock in focus on Friday

      Tata Elxsi, Anand Rathi Wealth, Den Networks, Active Clothing, Dr Reddy’s Laboratories, Bank of Baroda, Ugro Capital, Diksha Greens, Maruti Suzuki India, and Allied Blenders and Distillers will also be in focus on October 11.

    • Krsnaa Diagnostics: Creating new opportunities for itself

      With the ramp-up of new projects and fresh order wins, the current growth trajectory should continue into FY25-26

    • Krsnaa Diagnostics shares soar 4% on plans to acquire 23.53% stake in Apulki Healthcare

      Apulki Healthcare, incorporated in 2022, is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology, primarily under public-private partnership.

    • Krsnaa Diagnostics: Expanding addressable market with a B2C foray

      With the ramp-up of new projects, the current revenue growth trajectory should continue into FY25-26

    • Krsnaa Diagnost Consolidated June 2024 Net Sales at Rs 170.23 crore, up 21.96% Y-o-Y

    • Krsnaa Diagnost Standalone June 2024 Net Sales at Rs 163.16 crore, up 23.34% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347